• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Purple Biotech Ltd. - American Depositary Shares (NQ:PPBT)

    1.680 -0.070 (-4.00%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Purple Biotech Ltd. - American Depositary Shares

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    Purple Biotech's Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom ↗
    As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026. 
    Via Stocktwits
    News headline image
    Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Why Purple Biotech (PPBT) Stock Is Getting Hammered ↗
    Purple Biotech shares are trading lower by 28% during Tuesday's session. The company announced a $2.8 million offering. 
    Via Benzinga
    News headline image
    Why Purple Biotech (PPBT) Shares Are Trading Lower ↗
    Purple Biotech shares are trading lower by 11.5% during Monday's session. The company announced the exercise of warrants for $2 million gross proceeds. 
    Via Benzinga
    News headline image
    Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Why Is Purple Biotech Stock Trading Higher On Monday? ↗
    Purple Biotech's Phase 2 trial of CM24 in metastatic PDAC patients showed improved survival rates, biomarker responses, and disease control outcomes. 
    Via Benzinga
    News headline image
    Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    PPBT Stock Earnings: Purple Biotech Beats EPS for Q2 2024 ↗
    PPBT stock results show that Purple Biotech beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    News headline image
    Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
     
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.